FindTrial
Sign In

Master protocol for mantle cell lymphoma A multicenter phase II trial testing Gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma Protocol SAKK 36/03

Master protocol for mantle cell lymphoma A multicenter phase II trial testing Gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma Protocol SAKK 36/03

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-002860-43-IT
Enrollment
Unknown
Registered
2004-11-23
Start date
2005-03-31
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma MedDRA version: 6.1 Level: HLGT Classification code 10025323

Interventions

Trade Name: GEMZAR*INFUS 1FL 1G POLV Product Name: GEMCITABINA Product Code: NA Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Gemcitabine CAS Number: 122111-03-9 Current Sponsor code:

Sponsors

SIAK
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026